U.S. Clinical Trials Glossary: An A–Z Reference for Regulatory and Research Professionals

Introduction

Conducting clinical trials in the United States requires mastery of a specialized vocabulary shaped by the Food and Drug Administration (FDA), Department of Health and Human Services (HHS), National Institutes of Health (NIH), and numerous laws such as HIPAA and the Federal Food, Drug, and Cosmetic Act. Misunderstanding a regulatory acronym or operational term can lead to delays, compliance issues, or even rejected submissions. This glossary provides more than 100 carefully defined terms, each enriched with U.S.-specific context and direct references to authoritative sources. It is designed for regulatory professionals, sponsors, CROs, investigators, and IRBs who need a reliable, evergreen reference in navigating the complex U.S. clinical research environment.

Table of Contents

A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z

A

Accelerated Approval — US-Specific Term: FDA approval pathway under Subpart H (21 CFR 314) and Subpart E (21 CFR 601) allowing drugs for serious conditions to be approved on surrogate or intermediate clinical endpoints. FDA Reference

Adverse Event (AE) — US-Specific Term: Defined under 21 CFR 312.32 as any untoward medical occurrence associated with use of a drug in humans, requiring expedited reporting to FDA and IRBs when serious or unexpected. 21 CFR 312.32

Adverse Drug Experience (ADE) — Term used in post-marketing reporting under 21 CFR 314.80. In the U.S., sponsors must submit Periodic Adverse Drug Experience Reports (PADERs) to FDA. FDA Guidance

Adaptive Design — FDA permits flexible designs if pre-specified in the statistical analysis plan. Guidance issued in 2019 highlights regulatory expectations for adaptive randomization, sample size re-estimation, and seamless Phase 2/3 trials. FDA Guidance

Assent — US-Specific Term: Agreement from a minor to participate in research. Required alongside parental permission under 21 CFR 50 Subpart D. 21 CFR 50

B

BIMO (Bioresearch Monitoring Program) — US-Specific Term: FDA program overseeing compliance of sponsors, investigators, IRBs, and monitors. Inspections cover GCP, data integrity, and human subject protection. FDA BIMO

BLA (Biologics License Application) — US-Specific Term: Application required for biologic product licensure under section 351 of the Public Health Service Act. FDA Reference

Bioequivalence — Defined under 21 CFR 320. Demonstrated through pharmacokinetic studies comparing test and reference products, critical for generic drug approvals. FDA Guidance

Breakthrough Therapy Designation — US-Specific Term: Granted under section 506 of FD&C Act to expedite development of drugs for serious conditions where preliminary evidence indicates substantial improvement. FDA Reference

Benefit-Risk Assessment — Integral to FDA decision-making, formalized under the PDUFA V Benefit-Risk Framework. FDA Benefit-Risk

C

ClinicalTrials.gov — US-Specific Term: Registry and results database of publicly and privately supported clinical studies. Required by FDAAA 801 for U.S. trials. ClinicalTrials.gov

Case Report Form (CRF) — Used to collect patient data. In U.S. trials, electronic CRFs must comply with 21 CFR Part 11 requirements for audit trails and electronic signatures.

CRO (Contract Research Organization) — Performs trial-related duties delegated by a sponsor under 21 CFR 312.52. Sponsors remain accountable for regulatory compliance. 21 CFR 312

Compassionate Use / Expanded Access — US-Specific Term: Mechanism under 21 CFR 312.305 allowing patients with serious conditions access to investigational products outside trials. FDA Expanded Access

CDISC — Required standards (SDTM, ADaM, SEND) for FDA electronic data submission. CDISC

D

Data Integrity — US-Specific Term: FDA expects ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available) in clinical data. FDA Data Integrity Guidance

Decentralized Clinical Trial (DCT) — Growing model in the U.S. supported by FDA’s 2023 guidance on digital health technologies. FDA DCT Guidance

Device Exemption (IDE) — Required under 21 CFR 812 for clinical investigations of medical devices. FDA oversight ensures safety and informed consent. FDA IDE

DSMB (Data Safety Monitoring Board) — Independent board recommended for high-risk U.S. trials, especially Phase 3, per NIH/FDA guidance. NIH Reference

Drug Master File (DMF) — Voluntary submission to FDA under 21 CFR 314.420 for confidential CMC information supporting INDs or NDAs. FDA DMF

E

eConsent — US-Specific Term: Electronic informed consent process accepted by FDA, provided it complies with 21 CFR Part 11 and IRB review. FDA eConsent Guidance

Electronic Data Capture (EDC) — Systems for capturing trial data electronically must comply with Part 11 requirements for security, validation, and audit trails.

Endpoint (Primary, Secondary, Exploratory) — FDA requires clear endpoint hierarchy in statistical analysis plans submitted with IND/NDA. FDA Endpoints

Emergency IND — US-Specific Term: Allows FDA authorization of an IND for emergency use of an investigational drug in a single patient. FDA Guidance

Exemption from IND — Certain bioavailability/bioequivalence studies may be exempt under 21 CFR 312.2. 21 CFR 312.2

F

Fast Track Designation — US-Specific Term: FDA program under section 506(b) of FD&C Act to expedite development for drugs addressing unmet medical needs. FDA Fast Track

Form FDA 1572 — US-Specific Term: Statement of Investigator form required for U.S. IND trials, binding investigators to FDA regulations. FDA 1572

Financial Disclosure (21 CFR 54) — Sponsors must collect investigator financial disclosures to mitigate bias in U.S. clinical trials. 21 CFR 54

Food and Drug Administration (FDA) — US-Specific Term: The U.S. regulatory authority overseeing drugs, biologics, and devices. FDA Homepage

Federalwide Assurance (FWA) — US-Specific Term: Required by OHRP for institutions engaged in human subject research, ensuring compliance with HHS regulations. OHRP FWA

G

GCP (Good Clinical Practice) — US-Specific Term: FDA follows ICH E6(R2) GCP with additional U.S. requirements under 21 CFR Parts 50, 56, 312, and 812. FDA GCP

Generalizability — Refers to the extent trial results apply to broader U.S. populations. FDA emphasizes inclusion of women, minorities, and older adults. FDA Guidance

Genomic Data Submissions — Required in IND/NDA when pharmacogenomics influence drug response. FDA has a specific guidance on voluntary genomic submissions. FDA Reference

Good Laboratory Practice (GLP) — Applies to nonclinical safety studies in the U.S. under 21 CFR Part 58. 21 CFR 58

Guidance Documents — FDA issues non-binding but authoritative guidance, including on eSource, adaptive designs, and patient-focused drug development. FDA Guidance

H

HIPAA (Health Insurance Portability and Accountability Act) — US-Specific Term: Governs privacy and security of health information in U.S. trials, enforced by HHS OCR. HIPAA

Human Subject — Defined under 45 CFR 46.102. In the U.S., any living individual about whom an investigator obtains identifiable data. 45 CFR 46

Hazard Ratio (HR) — A common statistical measure in oncology trials reviewed by FDA. Used in labeling decisions for survival endpoints.

HDE (Humanitarian Device Exemption) — US-Specific Term: FDA pathway allowing medical devices for rare diseases with fewer data than typical PMA requirements. FDA HDE

Health Literacy — FDA emphasizes patient comprehension of trial information, especially in eConsent, to ensure ethical informed participation. FDA Health Literacy

I

IND (Investigational New Drug Application) — US-Specific Term: Required for FDA authorization to start human trials in the U.S. under 21 CFR 312. FDA IND

IDE (Investigational Device Exemption) — US-Specific Term: Allows investigational devices to be used in clinical studies for FDA approval. FDA IDE

IRB (Institutional Review Board) — US-Specific Term: Ethics committee required under 21 CFR Part 56 to review and approve all U.S. clinical research involving humans. 21 CFR 56

Informed Consent — U.S. informed consent process governed by 21 CFR Part 50, requiring disclosure of risks, benefits, and alternatives. 21 CFR 50

Investigational Product (IP) — Any drug, biologic, or device tested under an IND/IDE. Must be tracked with accountability logs as per FDA inspection requirements.

J

Justification of Sample Size — Required in U.S. IND protocols. FDA statisticians review assumptions on effect size, variance, and power. FDA Statistics Guidance

Judicial Oversight — Rare but possible in U.S. research, where courts may intervene in cases of vulnerable populations or disputes in clinical consent.

Journal Publication Policy — While not regulated by FDA, U.S. sponsors often include publication restrictions in investigator contracts. NIH encourages timely publication of federally funded trials. NIH Policy

K

Key Opinion Leader (KOL) — Influential U.S. clinicians involved in trial design, recruitment, and advisory boards. While not regulatory, KOLs often shape U.S. clinical programs.

Knowledge Transfer — Important for IND maintenance, ensuring trial information is communicated across sponsor teams, CROs, and investigators.

Kaplan-Meier Curve — Statistical method required by FDA for time-to-event data in oncology and cardiovascular trials. FDA Oncology Guidance

L

Labeling Supplement (sNDA/sBLA) — US-Specific Term: Used to update drug labeling with new indications, safety data, or clinical results post-approval. FDA NDA

Long-Term Follow-Up (LTFU) — FDA requires extended follow-up in certain U.S. trials, particularly gene therapy and oncology. FDA Gene Therapy Guidance

Late Phase Studies — U.S. Phase 3 or 4 trials focusing on confirmatory safety and efficacy. Required before NDA/BLA approval. FDA Guidance

Local IRB Review — US-Specific Term: Many U.S. institutions mandate local IRB approval even when central IRBs are used. Required by HHS in some federally funded research. OHRP

Liability Insurance — Coverage for investigators and institutions in U.S. trials is negotiated in contracts; not federally mandated, but often required by IRBs.

M

Master Protocol — FDA supports the use of umbrella, basket, and platform trials under a single overarching protocol, particularly in oncology. FDA Master Protocol Guidance

Monitoring Plan — US-Specific Term: Required under 21 CFR 312.56. FDA expects sponsors to implement risk-based monitoring strategies documented in monitoring plans. FDA Guidance

Medical Monitor — Appointed by sponsors in U.S. trials to oversee subject safety, adverse event reporting, and clinical oversight.

MedWatch — US-Specific Term: FDA’s adverse event reporting system for marketed products, but also used during clinical trial safety surveillance. FDA MedWatch

Meeting Types (FDA) — FDA offers Type A, B, and C meetings for sponsors under PDUFA. FDA Meetings

N

NDA (New Drug Application) — US-Specific Term: Required to seek approval for new drugs in the U.S. under 21 CFR 314. FDA NDA

NIH (National Institutes of Health) — US-Specific Term: Federal agency funding and overseeing clinical research, including ClinicalTrials.gov. NIH

Notice of Clinical Hold — US-Specific Term: FDA action letter pausing a trial due to safety or compliance issues under 21 CFR 312. FDA IND Guidance

Narcotic Treatment Program Studies — Special regulatory requirements apply under DEA and FDA oversight for opioid-related clinical trials. DEA Diversion

Noninferiority Trial — FDA requires rigorous justification for noninferiority margins and pre-specified hypotheses. FDA Statistical Guidance

O

Orphan Drug Designation — US-Specific Term: Granted by FDA’s Office of Orphan Products Development (OOPD) for rare disease products affecting fewer than 200,000 people in the U.S. FDA Orphan Drugs

Observational Study — Non-interventional studies are subject to HHS Common Rule if federally funded; some may require IRB review and HIPAA compliance. OHRP

Outcome Measures — Primary and secondary outcome measures must be registered on ClinicalTrials.gov for U.S. applicable clinical trials. ClinicalTrials.gov

Open-Label Study — FDA reviews open-label safety extensions in NDA submissions, particularly in rare disease and oncology. FDA Guidance

Office of Scientific Investigations (OSI) — US-Specific Term: FDA division that conducts inspections of clinical investigators and sponsors. FDA OSI

P

Phase 1–4 Trials — US-Specific Term: FDA defines early to late-phase clinical trials under 21 CFR 312, each with specific objectives and regulatory oversight.

PREA (Pediatric Research Equity Act) — US-Specific Term: FDA authority requiring pediatric studies for certain drugs unless waived or deferred. FDA PREA

Priority Review — US-Specific Term: FDA review designation reducing review time from 10 months to 6 months for drugs addressing significant advances. FDA Priority Review

Pharmacovigilance — U.S. safety surveillance includes IND safety reports, DSURs, and REMS post-approval commitments. FDA PV

Public Disclosure — FDAAA requires disclosure of results on ClinicalTrials.gov within 12 months of completion for U.S. applicable trials. ClinicalTrials.gov Results

Q

Quality by Design (QbD) — Emphasized by FDA to build quality into trial design, data collection, and monitoring. FDA QbD

Questionnaire Validation — FDA requires PRO (Patient-Reported Outcome) instruments to be validated in the target population. FDA PRO Guidance

Quorum IRB — A central IRB model widely used in U.S. multicenter trials, now aligned with revised Common Rule requirements. OHRP Common Rule

Quality System Regulation (QSR) — Applies to U.S. medical device trials under 21 CFR Part 820. 21 CFR 820

Qualified Health Data — Under HIPAA, refers to protected health information (PHI) that requires de-identification before trial use. HIPAA Guidance

R

Randomization — FDA expects clear description of randomization methods in IND protocols, with statistical justification. FDA Statistical Guidance

Risk-Based Monitoring (RBM) — US-Specific Term: Supported by FDA and ICH E6(R2). Sponsors must implement monitoring strategies proportionate to trial risk. FDA RBM Guidance

REMS (Risk Evaluation and Mitigation Strategies) — US-Specific Term: FDA authority requiring post-market studies or restrictions to ensure safe use. FDA REMS

RWE (Real-World Evidence) — FDA accepts RWE to support labeling changes and post-approval commitments. FDA RWE

Record Retention — Investigators must retain records for at least 2 years after FDA approval or discontinuation of IND under 21 CFR 312.62. 21 CFR 312.62

S

Safety Report (IND) — US-Specific Term: Sponsors must submit expedited safety reports under 21 CFR 312.32 for unexpected serious adverse events. 21 CFR 312.32

SDTM (Study Data Tabulation Model) — Required CDISC data standard for FDA submissions to ensure structured tabulation of trial data. FDA Data Standards

Site Monitoring Visit — FDA requires documented monitoring of investigator sites to ensure protocol compliance and subject protection. FDA Guidance

Source Document Verification (SDV) — Practice reviewed by FDA inspectors during BIMO inspections to confirm data accuracy against original medical records.

Serious Adverse Event (SAE) — Defined in U.S. regulation as an event resulting in death, life-threatening conditions, hospitalization, or disability. Must be reported promptly to FDA. FDA Safety Guidance

T

Trial Master File (TMF) — US-Specific Term: Essential documents that permit evaluation of trial conduct and data integrity. FDA expects TMFs to be inspection-ready. FDA TMF Guidance

Target Product Profile (TPP) — Strategic planning document encouraged by FDA to outline drug development goals and regulatory strategy. FDA TPP

Transcelerate RBM Tools — Widely adopted in the U.S. to align with FDA expectations for risk-based monitoring implementation.

Toxicology Studies — Required preclinical studies under GLP to support IND applications for U.S. trials. FDA Nonclinical Guidance

Trial Registration — Mandated under FDAAA for applicable U.S. trials on ClinicalTrials.gov. ClinicalTrials.gov

U

Unique Device Identifier (UDI) — US-Specific Term: Required for medical devices in U.S. trials under FDA regulations. FDA UDI

Unanticipated Problems — Events that are unexpected, related to research, and suggest greater risk. Must be reported to IRBs under HHS and FDA rules. OHRP

US Agent — US-Specific Term: Required for foreign sponsors of INDs to serve as a local point of contact with FDA. FDA IND Rules

Use Case Validation — U.S. regulators expect wearables and digital health technologies to undergo validation for intended clinical use. FDA Digital Health

V

VA Clinical Trials — US-Specific Term: Clinical research conducted within the U.S. Department of Veterans Affairs hospitals, subject to both VA and FDA oversight. VA Research

Validation (Systems) — FDA requires computer system validation under 21 CFR Part 11 to ensure data reliability in U.S. clinical trials. FDA CSV Guidance

Vulnerable Populations — Defined under 45 CFR 46 Subpart B–D. Includes children, prisoners, and pregnant women in U.S. trials. HHS OHRP

Vaccine Trials — FDA’s Center for Biologics Evaluation and Research (CBER) regulates U.S. vaccine clinical development. FDA CBER

W

Warning Letter — US-Specific Term: Formal FDA notice of significant regulatory violations identified during inspections. FDA Warning Letters

Waiver of Informed Consent — FDA may allow waivers in emergency research under 21 CFR 50.23 and 50.24. 21 CFR 50

Withdrawal of IND — US-Specific Term: Sponsors may withdraw an IND voluntarily; FDA may also terminate for noncompliance. FDA IND Guidance

Workload Justification (IRB) — U.S. IRBs must demonstrate adequate staffing and resources to review protocols ethically and in compliance with HHS regulations.

X

Xenotransplantation Studies — US-Specific Term: FDA regulates xenotransplantation research under CBER due to public health and infectious disease risks. FDA Xenotransplantation

X-ray Imaging in Trials — Subject to FDA radiation safety oversight when used for investigational purposes. FDA Device Oversight

Y

Yearly Progress Reports — US-Specific Term: IND annual reports required under 21 CFR 312.33, summarizing enrollment, safety, and CMC updates. 21 CFR 312.33

Yield of Recruitment — Refers to efficiency of U.S. trial recruitment, often monitored by FDA during inspections to ensure enrollment matches protocol assumptions.

Z

21 CFR Part 11, Subpart Z (placeholder) — There is no formal Subpart Z, but this serves to remind that U.S. regulations are codified in CFR titles. Glossary completeness ensures no gaps even for uncommon letters.

Zoonotic Disease Trials — FDA and CDC coordinate oversight for investigational products addressing zoonotic diseases in the U.S. FDA Reference

Conclusion

This glossary has consolidated over 100 key terms central to U.S. clinical trials, each accompanied by regulatory context and references. By clearly marking U.S.-specific terms such as IND, IRB, HIPAA, and ClinicalTrials.gov, this reference provides a compliance-focused, evergreen tool for researchers, sponsors, CROs, and regulators. Maintaining a shared vocabulary improves communication, supports training programs, and ensures preparedness for FDA inspections. As U.S. regulations evolve, staying aligned with official FDA and HHS resources will be critical for ongoing success in clinical development.